arrow
S

Sandra Tuyaerts

Vrije Universiteit Brussel
H指数:29
被引数:3,291

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity

胶质母细胞瘤中基于抗原敏感B7-H3-targeting纳米抗体的car-t细胞的临床前评估

2024-11-190
OAAI
A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)

一项关于在复发性高级别胶质瘤(rHGG)患者中,联合应用ipilimumab (IPI)和nivolumab (NIVO),并进行自体CD1c(BDCA-1)+/CD141(BDCA-3)+髓系树突状细胞(myDC)颅内给药的I期临床试验。

2024-09-010
PRE
Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial

在难治性晚期黑色素瘤患者中,通过瘤内(IT)途径给予自体CD1c(BDCA-1)+/CD141(BDCA-3)+髓样树突状细胞(myDC),联合免疫佐剂AS01B、ipilimumab(IPI)以及静脉注射nivolumab(NIVO):一项 Ib 期临床试验

2024-09-010
PRE
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade
2024-05-062
OAAI
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
2024-01-111
OAAI
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
2022-07-0482
OA